Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease

This study aimed to develop a new biodegradable stent for peripheral artery disease (PAD) that could provide sufficient radial force to maintain long-term patency and flexibility. All self-expandable hybrid biodegradable stents were designed by using a knitting structure composed of poly-L-lactic ac...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2016-01, Vol.2016 (2016), p.1-7
Main Authors: Jang, Yangsoo, Choi, Dong Hoon, Ko, Young-Guk, Park, Se-Il, Kim, Soon-Joong, Lee, Jung-Hee, Hong, Myeong-Ki
Format: Article
Language:English
Subjects:
Absorbable Implants
Angiography
Angioplasty
Animals
Biomedical research
Cardiology
Carotid arteries
Diagnostic imaging
Drug-Eluting Stents
Graft Occlusion, Vascular - diagnostic imaging
Graft Occlusion, Vascular - physiopathology
Laboratory animals
Medical imaging
Medicine
Methods
Nickel alloys
Organic acids
Peripheral Arterial Disease - diagnostic imaging
Peripheral Arterial Disease - physiopathology
Peripheral Arterial Disease - surgery
Polyesters - pharmacology
Stent (Surgery)
Stents
Studies
Swine
Swine, Miniature
Ultrasonography, Interventional
University colleges
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to develop a new biodegradable stent for peripheral artery disease (PAD) that could provide sufficient radial force to maintain long-term patency and flexibility. All self-expandable hybrid biodegradable stents were designed by using a knitting structure composed of poly-L-lactic acid (PLLA) and nitinol. Four different types of stents were implanted in 20 iliac arteries in 10 mini pigs as follows: a bare-metal stent (BMS) (group 1, n=5), a drug-free hybrid stent (group 2, n=5), a 50% (50 : 100, w/w) paclitaxel (PTX)/poly-lactide-co-glycolic acid (PLGA; fast PTX-releasing form) hybrid stent (group 3, n=5), and a 30% (30 : 100, w/w) PTX/PLGA (slow PTX-releasing form) hybrid stent (group 4, n=5). We performed follow-up angiography and intravascular ultrasonography (IVUS) at 4 and 8 weeks. In a comparison of groups 1, 2, 3, and 4, less diameter stenosis was observed in the angiographic analysis for group 4 at the 4-week follow-up (19.0% ± 12.7% versus 39.3% ± 18.1% versus 46.8% ± 38.0% versus 4.8% ± 4.2%, resp.; p=0.032). IVUS findings further suggested that the neointima of the patients in group 4 tended to be lesser than those of the others. Our new biodegradable 30% PTX/PLGA (slow-releasing form) stent showed more favorable results for patency than the other stent types.
ISSN:2314-6133
2314-6141
DOI:10.1155/2016/6915789